Faezeh Mozafari

Ms. Faezeh Mozafari

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2022 in Applied Organometallic Chemistry
Verified
Journal Article
Closed access
HNHamed Nosrati
Hamed Nosrati
MSMarziyeh Salehiabar
Marziyeh Salehiabar
FMFaezeh Mozafari
Faezeh Mozafari
JCJalil Charmi
Jalil Charmi
NENuri Erdoğan
Nuri Erdoğan
Yavuz Nuri ErtasYavuz Nuri Ertas
Yavuz Nuri Ertas

21 February 2023 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
FMFaezeh Mozafari
Faezeh Mozafari
HRHamid Rashidzadeh
Hamid Rashidzadeh
SBSoroush Bijani
Soroush Bijani
FZFaezeh Zare-Molaei
Faezeh Zare-Molaei
ZIZiba Islambulchilar
Ziba Islambulchilar
MHMir-Jamal Hosseini
Mir-Jamal Hosseini
Ischemic stroke is the most common among various stroke types and the second leading cause of death, worldwide. Edaravone (EDV) is one of the cardinal antioxidants that is capable of scavenging reactive oxygen species, especially hydroxyl molecules, and has been already used for ischemic stroke treatment. However, poor water solubility, low stability, and bioavailability in aqueous media are major EDV drawbacks. Thus, to overcome the aforementioned drawbacks, nanogel was exploited as a drug carrier of EDV. Furthermore, decorating the nanogel surface with glutathione as targeting ligands would potentiate the therapeutic efficacy. Nanovehicle characterization was assessed with various analytical techniques. Size (199nm, hydrodynamic diameter) and zeta potential (-25mV) of optimum formulation were assessed. The outcome demonstrated a diameter of around 100nm, sphere shape, and homogenous morphology. Encapsulation efficiency and drug loading were determined to be 99.9 and 37.5, respectively. In vitro drug release profile depicted a sustained release process. EDV and glutathione presence in one vehicle simultaneously made the possibility of antioxidant effects on the brain in specific doses, which resulted in elevated spatial memory and learning along with cognitive function in Wistar rats. In addition, significantly lower MDA and PCO and higher levels of neural GSH and antioxidant levels were observed, while histopathological improvement was approved. The developed nanogel can be a suited vehicle for drug delivery of EDV to the brain and improve ischemia-induced oxidative stress cell damage.

12 April 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SJSiamak Javani
Siamak Javani
MBMurat Barsbay
Murat Barsbay
MGMohammadreza Ghaffarlou
Mohammadreza Ghaffarlou
NMNavid Mousazadeh
Navid Mousazadeh
AMAli Mohammadi
Ali Mohammadi
HDHossein Danafar
Hossein Danafar

13 April 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
DGDaniela Alejandra Alambarrio Gonzalez
Daniela Alejandra Alambarrio Gonzalez
XLXiaohan Li
Xiaohan Li
SZSiara S. Zedonek
Siara S. Zedonek
SWSophia E. Willis
Sophia E. Willis
JPJordan N. Proctor
Jordan N. Proctor
JGJohn Gonzalez
John Gonzalez
Background/Objective: Delaying muscle fatigue could alleviate economic and food security, and welfare concerns associated with transporting market-weight pigs to harvest. Previous research demonstrates barrow nicotinamide riboside (NR) supplementation at varying doses during the last 10 d of finishing shows to be a countermeasure to muscle fatigue by reducing muscle fiber recruitment and increasing mitochondrial DNA expression in a dose-dependent manner. Therefore, this study aims to determine if a greater NR dose further enhances barrow fatigue resistance and characterize muscle mitochondria content and efficiency. Methods: Barrows (N = 87) were assigned to one of two dietary NR supplementation doses (TRT): 0 (0NR) or 150 (150NR) mg/kg body weigh NR administered during the last 14 d of finishing. Muscle (MUS) biopsies were collected on supplementation d (DAY) 0, 7 and 14 from three hind-leg muscles for NAD+ quantification and mitochondrial DNA expression and efficiency. On days 15 and 16, barrows were subjected to a performance test until they were subjectively exhausted. Electromyography data collection during the performance test were divided into five periods (PER) and included normalized root mean square (nRMS) from the same muscles. Results: There were no three-way interaction for nRMS (p > 0.83), but there were MUS × TRT and PER × TRT interactions (p < 0.05). During performance testing, 150NR had greater nRMS than 0NR in the bicep femoris (BF) and tensor fasciae latae (TFL; p < 0.01), but there were no differences in the semitendinosus (ST; p = 0.77). Treatments did not differ during PER 1 and 2 (p > 0.14) but 150NR had greater nRMS than 0NR during PER 3, 4 and 5 (p < 0.01) across all muscles. There was no three-way interaction for normalized (nNAD+; p = 0.14), but there was a DAY × TRT interaction (p < 0.05). There were no differences between 0NR and 150NR at d 0 (p = 0.95); however, by d 7 and 14, 150NR muscles had greater nNAD+ than 0NR muscles (p < 0.01). There tended to be a three-way interaction for mitochondrial DNA expression (p = 0.09). At supplementation d 14, all 150NR muscles had greater mitochondrial DNA expression and electron transport chain complex I and II activities (p < 0.01). When normalized to citrate synthase activity, electron transport chain complex I and II activity did not differ (p > 0.05). Conclusions: Large-dose NR supplementation appears to support sustained muscle fiber recruitment during prolonged activity and enhance fatigue resilience, primarily through increased NAD+ and mitochondrial biomarkers abundance and not through mitochondrial efficiency.